ArticleCureus2026
Utility of GATA3, Uroplakin-II, and p40 Markers in the Diagnosis of Urothelial Carcinoma.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background, aim, and objectives: Accurate diagnosis of urothelial carcinoma (UC), particularly in high-grade and limited biopsy specimens, may be challenging on morphology alone. Immunohistochemistry (IHC) markers such as GATA3, uroplakin II (UPII), and p40 may improve diagnostic confidence. This study aimed to evaluate the diagnostic utility of GATA3, UPII, and p40, individually and as a combined panel, in urothelial carcinoma, and to correlate marker expression with tumor grade and invasion status.
methodsThis cross-sectional study was conducted in the Department of Pathology, Sri Siddhartha Medical College (SSMC), Tumkur, Karnataka, India, over a period of 24 months from February 2024 to January 2026. The study included 35 consecutive histopathologically confirmed cases of urothelial carcinoma received in the Department of Pathology during the study period, diagnosed on transurethral resection of bladder tumor (TURBT) specimens and bladder biopsy specimens. Formalin-fixed paraffin-embedded tissue sections were stained with hematoxylin and eosin and subjected to IHC for GATA3, UPII, and p40. Positivity rates and staining intensity were assessed. Associations with grade and invasion were analyzed statistically. Data were entered into Microsoft Excel and analyzed using SPSS Statistics (IBM Corp., Armonk, NY, USA). Categorical variables were expressed as frequencies and percentages, while continuous variables were summarized as mean ± standard deviation. Associations between marker expression, tumor grade, and invasion status were analyzed using the chi-square test.
resultsThe mean age of the study population was 67.09 ± 5.77 years, with a male predominance (25/35, 71.4%). Low-grade urothelial carcinomas constituted 18/35 (51.4%) cases, while 17/35 (48.6%) were high-grade. Positive IHC expression was observed in 34/35 (97.1%) cases for UPII, 33/35 (94.3%) for GATA3, and 32/35 (91.4%) for p40. No statistically significant association was found between the expression of any marker and tumor grade or invasion status (p > 0.05). Triple-marker positivity was observed in 30/35 (85.7%) cases, dual-marker positivity in 4/35 (11.4%), and single-marker positivity in 1/35 (2.9%). No case was negative for all three markers, resulting in 100% diagnostic coverage with the combined IHC panel.
conclusionGATA3, UPII, and p40 are highly useful IHC markers in urothelial carcinoma. While each marker performed well individually, the combined panel demonstrated positivity in all cases in this cohort, suggesting complementary diagnostic value. This three-marker panel may be useful in difficult primary and metastatic cases requiring confirmation of urothelial differentiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.